Payment overview · 2025
General Payments
$805.12
32 reported records · 9 companies
Healthcare provider profile · identity verified
Ramon Deleon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ENGLEWOOD, FL · NPI 1750305561
Verified facts
What the public records show
CMS Open Payments records show Ramon Deleon, MD received $805.12 in general payments during 2025 across 32 reported records.
Cleerly, Inc. accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $214.14 | 26.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $188.67 | 23.4% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $146.96 | 18.2% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.43 | 17.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.91 | 3.6% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $23.65 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.06 | 2.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.89 | 2.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.41 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $800.12 | 31 |
| Education | $5.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $214.14 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $214.14 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $150.23 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $138.43 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.67 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $91.41 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $76.25 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.46 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.55 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.95 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 684 | 194 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 432 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 380 | 100 |
| Ezetimibe | Ezetimibe | 348 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 92 |
| Lisinopril | Lisinopril | 292 | 81 |
| Losartan Potassium | Losartan Potassium | 254 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 243 | 71 |
| Omeprazole | Omeprazole | 203 | 64 |
| Allopurinol | Allopurinol | 192 | 50 |
| Montelukast Sodium | Montelukast Sodium | 164 | 46 |
| Irbesartan | Irbesartan | 158 | 43 |
| Sertraline Hcl | Sertraline Hcl | 143 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 34 |
| Famotidine | Famotidine | 105 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 31 |
| Metformin Hcl | Metformin Hcl | 100 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 29 |
| Carvedilol | Carvedilol | 92 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 32 |
| Celecoxib | Celecoxib | 88 | 26 |
| Januvia | Sitagliptin Phosphate | 87 | 17 |
| Synthroid | Levothyroxine Sodium | 86 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 84 | 23 |
| Jardiance | Empagliflozin | 80 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 18 |
| Trazodone Hcl | Trazodone Hcl | 71 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 40 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 16 |
| Atenolol | Atenolol | 62 | 17 |
| Eliquis | Apixaban | 61 | 21 |
| Gabapentin | Gabapentin | 61 | 20 |
| Azelastine Hcl | Azelastine Hcl | 51 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 15 |
| Mirtazapine | Mirtazapine | 46 | 17 |
| Alendronate Sodium | Alendronate Sodium | 45 | 15 |
| Enalapril Maleate | Enalapril Maleate | 45 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 11 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 41 | 11 |
| Prednisone | Prednisone | 40 | 35 |
| Simvastatin | Simvastatin | 38 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 13 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 32 | 13 |
| Baclofen | Baclofen | 31 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | 12 |
| Furosemide | Furosemide | 30 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | 11 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Nexletol | Bempedoic Acid | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $805.12 · 32 records | Cleerly, Inc. | AIRSUPRA, BREZTRI, Cleerly Ischemia, Cleerly Labs, EVENITY, GEMTESA, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, UBRELVY, Veozah, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error